Trametinib (Mekinist▼): risk of gastrointestinal perforation and colitis

Use trametinib, authorised either as monotherapy or combined with dabrafenib, with caution in patients with risk factors for gastrointestinal perforation.

Letters sent to healthcare professionals in February 2016

In February 2016, a letter was sent to healthcare professionals regarding medicines containing valproate.

Posted on the  UK MHRA website on 10 March 2016